ES2178496T3 - Preparado con espectro terapeutico mejorado, con contenido en inhibidores de la sintesis de nucleoticos. - Google Patents

Preparado con espectro terapeutico mejorado, con contenido en inhibidores de la sintesis de nucleoticos.

Info

Publication number
ES2178496T3
ES2178496T3 ES99961041T ES99961041T ES2178496T3 ES 2178496 T3 ES2178496 T3 ES 2178496T3 ES 99961041 T ES99961041 T ES 99961041T ES 99961041 T ES99961041 T ES 99961041T ES 2178496 T3 ES2178496 T3 ES 2178496T3
Authority
ES
Spain
Prior art keywords
compound
group
halogen
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99961041T
Other languages
English (en)
Inventor
Jurgen Lindner
Burkhard Haase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Application granted granted Critical
Publication of ES2178496T3 publication Critical patent/ES2178496T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Preparado que contiene 1) al menos un compuesto que reduce esencialmente la circulación enterohepática de los inhibidores de la síntesis de nucleótidos, del grupo colestipol, colestiramina y carbón activo, o un compuesto que, de modo desplazado en el tiempo, antagoniza el efecto de los inhibidores de la síntesis de nucleótidos, del grupo uridina, purina, nucleótidos de purina o nucleótidos de pirimidina, y 2) al menos un inhibidores de la síntesis de nucleótidos del grupo 4-hexenoato de 2-morfolinoetil-(E)-6(1, 3-dihidro-4-hidroxi-6-metoxi-7-metil-3-oxoisobenzofuran-5-il)-4-metilo, mizoribina y compuestos de la fórmula I o II **(Fórmulas)** y/o una forma eventualmente estereoisómera del compuesto de la fórmula I o II y/o una sal fisiológicamente tolerable del compuesto de la fórmula II, en la cual R1 representa a) alquilo(C1-C4), b) cicloalquilo(C3-C5), c) alquenilo(C2-C6), o d) alquinilo(C2-C6), R2 representa a) -CF3, b) -O-CF3, c) -S-CF3, d) -OH, e) -NO2, f) halógeno, g) bencilo, h) fenilo, i) -O-fenilo, k) -CN, o l) -O-fenilo sustituido, una o varias veces, con 1) alquilo(C1-C4), 2) halógeno, 3) -O-CF3, o 4) -O-CH3, R3 representa a) alquilo(C1-C4), b) halógeno, o c) un átomo de hidrógeno, y X representa a) un grupo -CH, o b) un átomo de nitrógeno.
ES99961041T 1998-12-10 1999-12-01 Preparado con espectro terapeutico mejorado, con contenido en inhibidores de la sintesis de nucleoticos. Expired - Lifetime ES2178496T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19857009A DE19857009A1 (de) 1998-12-10 1998-12-10 Zubereitung mit verbesserter therapeutischer Breite, enthaltend Nukleotidsyntheseinhibitoren

Publications (1)

Publication Number Publication Date
ES2178496T3 true ES2178496T3 (es) 2002-12-16

Family

ID=7890633

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99961041T Expired - Lifetime ES2178496T3 (es) 1998-12-10 1999-12-01 Preparado con espectro terapeutico mejorado, con contenido en inhibidores de la sintesis de nucleoticos.

Country Status (30)

Country Link
EP (1) EP1137438B1 (es)
JP (1) JP2002531525A (es)
KR (1) KR20010080729A (es)
CN (1) CN1189214C (es)
AR (1) AR021577A1 (es)
AT (1) ATE218370T1 (es)
AU (1) AU766810B2 (es)
BG (1) BG105548A (es)
BR (1) BR9916006A (es)
CA (1) CA2354266A1 (es)
CZ (1) CZ20012029A3 (es)
DE (2) DE19857009A1 (es)
DK (1) DK1137438T3 (es)
EA (1) EA005136B1 (es)
EE (1) EE200100305A (es)
ES (1) ES2178496T3 (es)
HK (1) HK1041598B (es)
HR (1) HRP20010429A2 (es)
HU (1) HUP0104624A3 (es)
IL (1) IL143586A0 (es)
MX (1) MXPA01005861A (es)
NO (1) NO20012719L (es)
NZ (1) NZ511882A (es)
PL (1) PL349336A1 (es)
PT (1) PT1137438E (es)
SI (1) SI1137438T1 (es)
SK (1) SK284842B6 (es)
WO (1) WO2000033876A1 (es)
YU (1) YU39901A (es)
ZA (1) ZA200104815B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate
JP4382354B2 (ja) * 2001-03-13 2009-12-09 ヴァルブルク・グリコムド・ゲーエムベーハー 1−ブタン酸誘導体およびその使用
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
AU2003261354A1 (en) * 2002-08-02 2004-02-23 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
JP2005538165A (ja) 2002-09-06 2005-12-15 シェボ ビオテック アクティエン ゲゼルシャフト 解糖酵素及び/又はアミノ基転移酵素錯体調節用化合物
JPWO2005060980A1 (ja) * 2003-12-24 2007-12-13 正彬 少名子 疾患治療用医薬及び糖尿病治療用医薬
DE102005017592A1 (de) * 2005-04-16 2006-10-19 Lindner, Jürgen, Dr. med. Darreichungsformen und Kombinationspräparate von Pyrimidinbiosyntheseinhibitoren zur Erzielung zusätzlicher Wirkungen auf das Immunsystem
EA015952B1 (ru) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
ES2079765T3 (es) * 1991-10-23 1996-01-16 Hoechst Ag Derivados de amidas de acido n-fenil-2-ciano-3-hidroxicrotonico y su utilizacion como medicamento con propiedad inmunomoduladora.
IT1254519B (it) * 1992-03-16 1995-09-25 Chiesi Farma Spa Associazioni di composti ad attivita' antivirale
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
AU4596097A (en) * 1996-09-26 1998-04-17 Williams, James W. Improved therapeutic uses of 4-quinoline-carboxylic acid derivatives

Also Published As

Publication number Publication date
PL349336A1 (en) 2002-07-15
KR20010080729A (ko) 2001-08-22
DE59901681D1 (de) 2002-07-11
HRP20010429A2 (en) 2002-06-30
NO20012719D0 (no) 2001-06-01
SK7882001A3 (en) 2001-12-03
EE200100305A (et) 2002-08-15
EA005136B1 (ru) 2004-12-30
HUP0104624A2 (hu) 2002-04-29
DE19857009A1 (de) 2000-06-15
HK1041598B (zh) 2005-07-15
NZ511882A (en) 2003-11-28
EP1137438A1 (de) 2001-10-04
HUP0104624A3 (en) 2002-12-28
SK284842B6 (sk) 2005-12-01
AR021577A1 (es) 2002-07-24
IL143586A0 (en) 2002-04-21
EP1137438B1 (de) 2002-06-05
YU39901A (sh) 2005-06-10
JP2002531525A (ja) 2002-09-24
AU766810B2 (en) 2003-10-23
BG105548A (en) 2001-12-29
BR9916006A (pt) 2001-09-04
AU1779300A (en) 2000-06-26
WO2000033876A1 (de) 2000-06-15
CA2354266A1 (en) 2000-06-15
CZ20012029A3 (cs) 2002-02-13
MXPA01005861A (es) 2002-03-27
DK1137438T3 (da) 2002-10-14
SI1137438T1 (en) 2002-08-31
CN1189214C (zh) 2005-02-16
ZA200104815B (en) 2002-06-13
NO20012719L (no) 2001-06-01
CN1329506A (zh) 2002-01-02
PT1137438E (pt) 2002-11-29
ATE218370T1 (de) 2002-06-15
HK1041598A1 (en) 2002-07-12
EA200100647A1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
YU37903A (sh) POSTUPCI LEČENJA STANJA POVEZANIH SA p38 KINAZOM I JEDINJENJA PIROLOTRIAZINA KOJA SE KORISTE KAO INHIBITORI KINAZE
NL350075I2 (es)
PL371515A1 (en) Hif hydroxylase inhibitors
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
JP2004506606A5 (es)
TR200003039T2 (tr) Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
TW200500373A (en) 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PL365285A1 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
DE60130023D1 (de) Behandlung der nebenwirkungen von statinen
RS113904A (en) 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CY1105788T1 (el) Χρηση του taci σαν παραγοντα καταπολεμησης ογκων
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
HK1043311A1 (zh) 使用替代-1,5-二脫氧-1,5-亞氨基-d-glucitol化合物治療肝炎病毒感染
HK1088891A1 (en) 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
WO2002009715A3 (en) Use of an arylaldehyde 5-oxo-1, 2, 4-triazine hydrazide for the treatment of cancer
NO20033145D0 (no) Purinderivater som purinergiske reseptorantagonister
BR9907882A (pt) Uso de compostos de 1,5-didesóxi-1,5-imino-d-glucitol n-substituìdos para o tratamento de infecções de vìrus de hepatite
ES2178496T3 (es) Preparado con espectro terapeutico mejorado, con contenido en inhibidores de la sintesis de nucleoticos.
WO2005007103A3 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
GB0100620D0 (en) Chemical cokpounds V
MXPA03009602A (es) Analogos de nociceptina.